

Erratum to: Erenumab for the Prevention of Migraine, Including the Rationale, Findings and Clinical Implications of the LIBERTY Study

Uwe Reuter

Charité Universitätsmedizin Berlin, Berlin, Germany



Citation: *European Neurological Review.* 2020;15(1):[online only]

Erratum to: *European Neurological Review.* 2019;14(2):68–71 DOI: <https://doi.org/10.17925/ENR.2019.14.2.68>

In the originally published article there was an error in Table 1. The reduction in monthly migraine days over 12 weeks versus placebo with quarterly fremanezumab was incorrectly given as “-0.6”; this should read “-3.7”. □